SDI Announces Participation of Berlex in Its Genomic Antibodies™ Initiative
News Apr 21, 2006
Under terms of this amended agreement, SDI will provide polyclonal and monoclonal Genomic Antibodies™ to Berlex.
Matthew H. Knight, President and CEO of Strategic Diagnostics commented, "We are extremely pleased to have a world-class company recognize the utility of Genomic Antibodies™."
"The SDI Genomic Antibodies™ process significantly reduces the time required to produce a custom antibody for Berlex and Genomic Antibodies™ are successfully produced to traditionally difficult antigen targets such as transmembrane proteins, membrane-associated proteins and highly conserved proteins, which will help Berlex to identify and market new pharmaceuticals more quickly."
Mr. Knight continued, "We are just beginning our commercial efforts for this exciting new offering and continue to interact with a number of significant companies and research initiatives."
"We believe we bring significant value to our customers by decreasing the time to deliver new diagnostics and or therapeutics to the market."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.